Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of
cardiomyopathy are common presenting features, and patients often are referred to …

Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among
them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per …

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the
accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an …

Systemic AL (light chain) amyloidosis is a rare protein misfolding disorder associated with
plasma cell dyscrasia affecting various organs leading to organ dysfunction and failure. The …

Cardiac amyloidosis is a rare, debilitating, and usually fatal disease increasingly recognized
in clinical practice despite patients presenting with non-specific symptoms of …

Background We conducted a cross-sectional study to characterize health-related quality of
life and symptom burden in individuals living with light chain (AL) amyloidosis. Methods …

Background Light chain (AL) amyloidosis is a plasma cell neoplasm associated with high
early mortality and severe morbidity that can cause severe disability. We explored the impact …

Introduction: SystemicAL amyloidosis is a progressive and often fatal disease caused by
misfolded light chains that aggregate into amyloid fibrils and deposit in vital organs, leading …

In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib,
cyclophosphamide, and dexamethasone (D‐VCd) had significantly higher rates of organ …

Introduction: Treatment of amyloid light-chain (AL) amyloidosis, a rare disease with a< 5-
year lifespan, remains challenging. This systematic literature review (SLR) aimed to …